Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia - Wikidata - awgldk - TriplyDB

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

http://www.wikidata.org/entity/Q24634360

about

Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics On the Quest of Cellular Functions of PEA-15 and the Therapeutic Opportunities Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells Novel agents in Waldenström macroglobulinemia.eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs Elevated NIBP/TRAPPC9 mediates tumorigenesis of cancer cells through NFκB signaling Novel agents in Waldenstrom Macroglobulinemia.How to manage Waldenstrom's macroglobulinemia.Targeting the PI3K-AKT-mTOR signaling network in cancer.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Signal transduction inhibitor therapy for lymphoma.Emerging drugs for Waldenström's macroglobulinemia.Signaling to the ribosome in cancer--It is more than just mTORC1.Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.Utility of mTOR inhibition in hematologic malignancies.Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.Targeting the bone marrow in Waldenstrom macroglobulinemia.mTOR kinase inhibitors as a treatment strategy in hematological malignancies.Risk stratification in Waldenström macroglobulinemia.Current clinical development of PI3K pathway inhibitors in glioblastoma.Perifosine in renal cell carcinoma.Waldenström macroglobulinaemia: the key questions.Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Novel treatment options for Waldenström macroglobulinemia Waldenström macroglobulinemia: from biology to treatment.Current and future therapeutic approach for Waldenström's macroglobulinemia.

P2860

Q26740191-FDAF0151-3B7A-4A17-9BAC-FA6E80968317 Q26766293-20CBB974-6EDC-48D7-BA82-6755DC374A61 Q26776391-0BA429B6-031B-4C86-B458-669CBE5C9774 Q26799216-C410D5C9-8FAE-4158-819F-4BE18B85D380 Q26829652-D03F1059-B738-4DFB-B892-189C1560322D Q28291793-86F5E83E-3862-4370-AB56-62C800031BFE Q33395066-0FBFB393-3A45-4D9F-BE86-120D7BBCA93A Q33400780-09B4F865-92AB-4CAD-9E43-B46D01B4605C Q33408517-A01705F9-FF88-468F-833B-E7F587B1CA69 Q33414529-EEAC4435-2A19-4C0A-9EA6-2D8B97C00295 Q33421444-E91D398F-161A-463A-93A6-69A037468CDC Q33438490-A4DA8F29-8ACF-4063-9016-777EB19F50B2 Q34172071-CB01829D-9941-4643-89F7-A97F7FFAD559 Q34215333-BD084AAE-3530-40DD-9DD7-640BAC0FD0EA Q34852951-B268A063-8B36-4A73-8676-5996403D8344 Q35429544-C9F60191-D73E-4DF8-B19E-1CCAC0F7193D Q35534450-175CB760-6629-47EE-A4C4-F864A42EE454 Q35640098-1F22F9F1-4A78-4956-9716-B63D20B36D01 Q35742493-12824B65-7E25-4F4D-8063-0B499EC7DD90 Q36117791-396F2A6E-0269-4F79-9F07-0145ADA91B1F Q36764811-3852F9FF-9C55-4620-B31F-3A814F5FB6BE Q37353968-C0E6F401-0ADF-4044-9457-F0F62B11A773 Q37727180-57305272-F88E-48A3-832B-5394ED4891CE Q37829224-4B688BD1-65C2-40CC-8560-6A2833AD7249 Q37847176-27E306BD-9933-47DF-938C-29F893EA0B0F Q37848287-3BD38C1F-97B1-456D-B29E-FBE4028D49FA Q37872655-0FB3C7F4-2769-45E8-9AB8-5672F42B64A9 Q37883723-B5BE3089-4931-4A50-A3E8-F4B1C28B37CE Q37923308-FEF9EFBB-ACA9-4DC1-AD50-5DC381AB9EAE Q37950586-57594AE3-00C3-4415-A1AE-494DF7621874 Q37993588-D9CC2EEF-41B5-42B2-838C-082740F1E216 Q37999886-B53319A4-38FB-4B59-89AA-38656F5478E5 Q38012438-EF6A8437-FB00-44AC-9AC9-45CAD666B5DB Q38068572-E5A96144-FA28-4400-AA2B-0845E8750CA0 Q38104808-A684DA5C-48EB-432D-9CFD-3E96215DC36A Q38150849-B1D1E9CA-805B-47DD-BD6D-E6940CA452A4 Q38150876-84A1BEE9-40CF-463A-8223-FA694036C234 Q38167433-C0AC01E9-6085-40A8-BADE-DADE3BC905C9 Q38176969-2081E6A0-75DE-4CCD-8879-96DE093574E6 Q38206820-91D25DCF-8AC5-443C-A447-73F58757D801

P2860

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia

http://www.wikidata.org/entity/Q24634360

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@ast

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@en

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@nl

type

label

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@ast

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@en

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@nl

prefLabel

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@ast

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@en

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@nl

P1433

Q24634360-22DD2CC4-88EB-4643-BAD9-7BD1804F7C79

P1476

Q24634360-A0DF76E5-FAA0-4CD0-A3E1-2171E3299C8B

P2093

Q24634360-0C6DBDAC-C787-4D0E-9DF4-2437522EAEEA

Q24634360-0E2FC45D-129F-4E1C-880E-0EE08796648B

Q24634360-1188B413-7166-464C-9BD9-E4DD8AC6F636

Q24634360-1A9AF32D-0A25-4CA0-8F76-0369509466AE

Q24634360-45D2D1F1-36C3-4883-ACB5-81BC465A6359

Q24634360-7BACBBC1-2149-4B9E-91C7-E6B818108969

Q24634360-80FDE0C0-C37A-4491-A73E-99DA2E99F1FB

Q24634360-817FFDF1-1A8B-426D-A596-BB3A02B663CD

Q24634360-82C00EE1-36AE-467B-BFC1-21711494520A

Q24634360-B66641A9-FC33-4750-914A-0BDDDFAE8346

P2860

Q24634360-02D9749C-DE18-4085-BC43-211FDB4F36CA

Q24634360-041C1169-58C6-4431-89BA-82902C590873

Q24634360-0865FF27-BD8F-4366-911B-8DDACE431EB6

Q24634360-0AB09112-915E-4C23-B9D5-2550944CA5F5

Q24634360-1B723B2A-B040-4BD1-BCE0-90382F4D6C16

Q24634360-206D8BDE-290B-4E52-A959-B811EF862121

Q24634360-28963885-DB1F-4D87-94B5-7231587C8EC9

Q24634360-42A165F1-BF7B-41C7-BAE2-BADC23561B17

Q24634360-43A60A07-579E-4805-99F5-BE83CD9FCC16

Q24634360-53314BD7-7A88-4EAD-869D-131270C52B76

P304

Q24634360-3658A6FD-6CB9-463E-B0FB-A7EC9E426823

P31

Q24634360-8F5523C2-FED9-43A0-AEE5-7BF8E6D5A46B

P3181

Q24634360-EF4DACED-38F2-4482-B39A-A8886CF721E3

P356

Q24634360-DCA8F2A1-D5C5-4A5F-9664-FDDC4FF672D1

P407

Q24634360-CAA9C92D-183C-4AAE-BE3D-FA05F69F369F

P433

Q24634360-3AE6B146-ECDB-4EBB-978A-92E643F282F0

P478

Q24634360-3FD32D71-F341-48C3-8374-91A1566F3C8D

P50

Q24634360-03D350D2-A329-40D2-BE66-C54B358AB0D1

Q24634360-11228D20-23ED-4FD5-B969-835921C539FE

Q24634360-407A6319-37BD-484F-9A08-064C108A2221

Q24634360-449A56A7-9283-4B46-80F3-937A0CEC4D54

Q24634360-518D4B7B-7D70-48B1-87AE-C483CBBD9412

Q24634360-ACBF002D-B917-4EE1-BD1D-AA42B752BBB4

P577

Q24634360-3E239F2F-68D5-4AB1-A428-3E9B354560DE

P698

Q24634360-6C17EA09-8364-4827-ACDA-6661D73BD39D

P921

Q24634360-61B696E1-97C3-4FD4-8FFE-620ACCDF0A8C

P932

Q24634360-A4719F2C-7F87-4C26-93AF-96CCB9F332FF

P3181

P356

1078-0432.CCR-09-1837

P1433

Clinical Cancer Research

P1476

Clinical and translational stu ...... aldenstrom's macroglobulinemia

@en

P2093

Abdel Kareem Azab

http://www.w3.org/2001/XMLSchema#string

Diane Warren

http://www.w3.org/2001/XMLSchema#string

Edie Weller

http://www.w3.org/2001/XMLSchema#string

Fangxin Hong

http://www.w3.org/2001/XMLSchema#string

Feda Azab

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Lyuba Varticovski

http://www.w3.org/2001/XMLSchema#string

Meghan Rourke

http://www.w3.org/2001/XMLSchema#string

Nancy Rubin

http://www.w3.org/2001/XMLSchema#string

Peter Sportelli

http://www.w3.org/2001/XMLSchema#string

P2860

Waldenström macroglobulinemia

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Diagnosis and management of Waldenstrom's macroglobulinemia

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia

How I treat Waldenström macroglobulinemia

Targeting NF-kappaB in Waldenstrom macroglobulinemia

Exploiting the PI3K/AKT pathway for cancer drug discovery

Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

P304

1033-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

633343

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-09-1837

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20103671

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

2885252

http://www.w3.org/2001/XMLSchema#string